Predicting the risk of venous thromboembolism recurrence

John A. Heit

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Venous thromboembolism (VTE) is a chronic disease with a 30% ten-year recurrence rate. The highest incidence of recurrence is in the first 6 months. Active cancer significantly increases the hazard of early recurrence, and the proportions of time on standard heparin with an APTT ≥ 0.2 anti-X a U/mL, and on warfarin with an INR ≥ 2.0, significantly reduce the hazard. The acute treatment duration does not affect recurrence risk after treatment is stopped. Independent predictors of late recurrence include increasing patient age and body mass index, leg paresis, active cancer and other persistent VTE risk factors, idiopathic VTE, antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiency, hyperhomocysteinemia and a persistently increased plasma fibrin D-dimer. A recommendation for secondary prophylaxis should be individualized based on the risk for recurrent VTE (especially fatal pulmonary embolism) and bleeding. The appropriateness of secondary prophylaxis should be continuously reevaluated, and the prophylaxis stopped if the benefit no longer exceeds the risk.

Original languageEnglish (US)
Pages (from-to)S63-S67
JournalAmerican journal of hematology
Issue numberSUPPL. 1
StatePublished - May 2012

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Predicting the risk of venous thromboembolism recurrence'. Together they form a unique fingerprint.

Cite this